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etiological agents of AIDS in humans. The viral envelope glycoproteins gpl20 and 
gp41 mediate the early virus-cell interaction of HIV with the target cells. The 
envelope glycoprotein is organised into trimeric complexes on the virion surface 
and the heavily glycosylated gpl20 contains both N- and O-linked glycans. The 
glycosylation is necessary for generation of correct conformation but it is also an 
important component to decrease the susceptibility of the virus to immune 
responses of the host. These and other factors are likely to influence the 
progression of the natural infection in HIV infected individuals. Several aspects of 
N-linked glycans and O-linked glycans of gpl20 were investigated. 
We characterised two N-glycan in the VI-loop and V3-loop of gpl20 and found 
both N-glycans to be of the complex type. Further, these N-glycans was found to 
influence the sensitivity of the virus to neutralising antibodies. We deleted all 
potential O-glycan sites in the V3-loop of gpl20, to pin-point the unknown 
location of broadly O-linked neutralisation epitopes of gpl20. However, the 
location of these neutralisation epitopes must be outside of the V3-loop. Using a 
novel deglycosylation assay, we identified N-glycans located in the vicinity of the 
CD4 binding site and epitopes on gpl20 recognised by antibodies from HIV 
infected individuals. However, these recognition sites were found to be only partly 
overlapping. These antibody responses are likely to influence the progression of 
infection in HIV infected individuals, but the presence of autologous neutralising 
antibodies was not a requirement in persons displaying a slow progressing HIV 
infection. However, a non-syncytium viral phenotype in conjunction with a mutant 
allele carrying a 32 base pair deletion in the CCR5 co-receptor gene, was found to 
be predictive for slow progressing infection. 
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Abbreviations 
Ab Antibody 
AIDS Acquired immune deficiency syndrome 
CCR5 ß-chemokine receptor - coreceptor for HIV 
CD4 Cluster of differentiation antigen 4; cell membrane molecule; 
receptor for HIV 
CD4bs CD4 binding site - the region of gp 120 interacting with CD4 
CXCR4 ß-chemokine receptor - coreceptor for HIV 
D7324 Antibody against the C5 region of gpl20 
DNA Deoxyribonucleic acid 
ELISA Enzyme-linked immunosorbent assay 
gp Glycoprotein 
HIV Human immunodeficiency virus 
HIV Ig Immunoglobulins from HIV infected individuals 
HTLV Human T-cell leukemia virus. 
HAART Highly active antiretroviral therapy 
Ig Immunoglobulins 
2G12 Human anti-gpl20 M Ab directed against a discontinous epitope of 
gpl20195 
LTNP Long-term nonprogressors 
MAb Monoclonal antibody 
NEA9205 Antibody against the tip of the V3 loop of gpl20 
NSI Non-syncytium inducing 
P4/D10 Antibody against the V3 loop of gp 1201 
PCR Polymerase chain reaction 
RIPA Radio-immuno-precipitation-assay 
RNA Ribonucleic acid 
RPI Rapid progressing infection 
sCD4 Recombinant soluble form of the CD4 molecule 
SI Syncytium inducing 
SIV Simian immunodeficiency virus 
SPI Slow progressing infection 
Th epitope T-helper cell epitope 
Tn O-linked carbohydrate neo-antigen, GalNac-Ser/Thr 
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Brief introduction & Aims 
The human immunodeficiency virus (HIV), is the etiological agent of acquired 
immunodeficiency syndrome (AIDS). The virus expresses on the surface the 
viral glycoprotein, gpl20 that is important in the early virus-cell interactions for 
infection of target cells. The extensive glycosylated gpl20 molecule is modified 
by both N-Iinked and 0-1 inked glycans that have structural as well as functional 
roles. Some of the O-linked glycans can serve as neutralising structures, but 
their location on gp 120 still remains unknown. On the other hand, the more 
bulky N-linked glycans can modulate the accessibility and recognition of 
antibodies to gpl20. Available data suggests that N-glycosylation significantly 
contributes to the viral escape from the immune responses in HIV infected 
individuals. However, other factors are likely to influence the progression of the 
HIV infection. 
The aims of this dissertation were: 
1. To characterise the role of a defined N-linked glycan strategically located in 
the triple-nested S-S bridged VI region of gpl20, and to structurally classify 
this particular glycan. 
2. To determine whether the broadly reactive carbohydrate gpl20 neutralisation 
targets, consisting of short O-glycan neoantigens, are localised in the V3 
region. 
3. To establish a method for determining N-linked glycan accessibility after 
antibody binding to gpl20 and appreciate the density of glycans in the 
vicinity of neutralising epitopes and the CD4-binding domain. 
4. To apply this assay and a crossed neutralisation assay, combining 
consecutive pairs of sera and HIV-1 isolates from patients for analysis of 
disease progression in HIV-infected individuals. 
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General background 
Retroviruses 
Retroviruses are RNA viruses, characterised by their ability to create a DNA 
copy of their viral RNA genome, which later becomes integrated in the host cell 
chromosomes. Retroviruses have probably existed for millions of years, but it 
was not until the late 1960's that retroviruses were identified as a special family 
of RNA viruses through discovery of the reverse transcriptase in Murine 
leukemia virus and Rous sarcoma virus10;I93. David Baltimore and Howard 
Temin received the Nobel for this discovery in 1975. In 1980, the first human 
pathogenic retrovirus, Human T-cell leukemia virus, was identified159'160 and 
only a few years later the human immunodeficiency virus type 1 (HIV-1) was 
identified by French and American scientists11;60;101;197. 
Retroviruses have been identified for all vertebrate species and have been 
categorised based on their morphology in electron microscopy16'63: 
A-type: 'Intracisternal particles'. Non-enveloped, immature particles only seen 
inside cells, believed to result from endogenous retrovirus-like genetic elements. 
B-type: Enveloped, extracellular virus particles with a condensed, acentric core 
and prominent envelope spikes, e.g. MMTV. 
C-type: As B-type, but with a central core and barely visible spikes - e.g. most 
mammalian and avian retroviruses (MLV, ALV, HTLV, HIV). 
D-tvpe: Usually the largest virus particle (to 120 nm) and spikes less prominent, 
e.g. MPMV. 
An improved understanding of the genetic relationships between retroviruses 
resulted in a classification into several orders, suborders, families and genera (79 
and ICTV web: www.ncbi.nml.nih.gov/ICTV/) (Table 1). 
.9. 
Retroelementopsida 
Retrovirales 
Orthoretroviridae 
Retroviridae 
Alpharetrovirus Avian leukosis virus 
Betaretrovirus Mouse mammary tumor virus 
Gammaretrovirus Murine leukemia virus 
Deltaretrovirus Bovine leukemia virus 
Epsiloretrovirus Walley dermal sarcoma virus 
Lentivirus Human immunodeficiency virus 1 Bovine immunodeficiency virus (BIV) 
Equine infectious anemia virus (EIAV) 
Feline immunodeficiency virus (FIV) 
Caprine arthritis encephalitis virus (CAEV) 
Visna/maedi virus 
Human immunodeficiency virus 1 (HIV-1) 
Human immunodeficiency virus 2 (HIV-2) 
Simian immunodeficiency virus (SIV) 
Spumavirus Human spumavirus 
Table Fejl! Ukendt argument for parameter.. Classification and genera of vertebrate retroviruses. 
Members of the lentivirus genus is shown. Modified from Hull, 1999 79. 
Retroviruses share a common basic genetic composition of gag (structural), pol 
(enzymatic) and env (envelope) genes flanked by two long terminal repeats 
(LTR) (Fig. 1). 
LTR gag pol env . LTR 
Figure Fejl! Ukendt argument for parameter.. Basic composition of the retroviral genome. The gag, pol, and 
enc genes in the provirus is flanked by two long terminal repeats, LTR. Modified from Wain-Hobson, S. et 
al., 1985 197 
The retroviral gene products have common functions and locations in the virus 
particle (Table 2 and Figure 2). 
ÜMI •H Protein Function 
gag MA matrix matrix protein; lines envelope 
gag CA capsid capsid protein; protects the core; most abundant protein in virus particle 
gag NC nucleocapsid. nucleocapsid protein; protects the genome; forms the core 
pof PR Protease Essential for qag protein cleavaqe durinq maturation of the viral particle 
pol RT Reverse transcriptase Reverse transcribes the RNA qenome; has RNAseH activity 
pol IN Inteqrase Needed for inteqration of the provirus 
env SU surface glycoprotein The outer envelope glycoprotein; major virus antigen 
env TM transmembrane protein The inner component of the mature envelope glycoprotein 
Table Fejl! Ukendt argument for parameter.. Names and functions of retroviral gene products. Modified 
from Freed, 1998 57. 
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membrane 
protease 
transmembrane envelope protein 
(gP41,TM) 
surface envelope protein  
(gp120, TM) 
matrix 
(p17, MA) 
nucleocapsid (p7, NC) 
RNA genome 
capsid (p24, CA) 
transcriptase 
(p66/p51, RT) 
Figure Fejl! Ukendt argument for parameter.. Composition of the retroviral particle. The viral proteins are 
highly organised in the viral particle. The HIV-1 particle is shown. Modified from Freed, 1998 57. 
HIV-1 and HIV-2 
A few years after the identification of HIV a homologous, but distinct, type of 
HIV was identified in Africa34,92. This HIV virus was termed HIV type 2 (HIV-
2). HIV-1 appear to be the result of multiple zoonotic transmissions of humans 
from SIV infected non-human primate chimpanzees, whereas HIV-2 appear to 
be originating from non-human sooty mangabeys. The zoonotic event believes 
/"t .£').OQ.'11 "3 
to have occurred around 1931 ' ' ' . This estimate coincides with the French 
colonisation of equatorial Africa, that may have increased the risk factors for 
zoonotic transmission of HIV-132. 
HIV-1 and HIV-2 are classified as slowly pathogenic viruses, lentiviruses. This 
genus includes other mammalian retroviruses, such as EIAV (Equines, horses), 
CAEV (caprines, goats), Visna/maedi virus (ovines, sheeps), BIV (bovines, 
cattle), FIV (felines; cats) SIV (simian, monkeys)63'141 (Table 1). 
-  1  -
AIDS epidemic 
The acquired immunodeficiency syndrome (AIDS) was first described in the 
beginning of 1980's where immunodeficiency-associated conditions, such as 
Pneumocystis carinii pneumonia, Kaposis sarcoma, candidia albicans, and 
chronic herpes simplex lesions, were found in male homosexuals and 
intravenous drug abusers64;80;1,7;184. In the following years, the number of AIDS 
cases increased rapidly and now it was also found among haemophiliacs, blood 
transfusions recipients and sex partners of AIDS patients too. In 1983/1984 the 
HIV virus was isolated from AIDS patients, and the etiological agent of AIDS 
was identified. 
By the end of 1999, the total number of HIV-infected individuals was estimated 
to be about 34.2 million. During the year 1999, more than 5.4 million had been 
infected with HIV and approximately 2.8 million had died of AIDS. 
Accumulated, 18.8 million people have died of HIV/AIDS in the 20th century 
and over 53 million people have been infected with HIV (www.unaids.org). 
Clinical course and parameters of HIV-1 infection 
The clinical course of HIV infection begins with exposure to HIV. Humans are 
exposed to and infected with HIV via different routes (in alphabetical order): 
artificial insemination, birth, blood contaminated syringes, blood transfusions 
(blood derivatives in medicine), breast milk, intimate sexual contact, in utero, 
transplantation. Intimate sexual contact is the primary route of HIV infection. 
The natural HIV infection is chronic and will eventually lead to death of the 
infected individual. The clinical course of HIV infection is divided into several 
phases; Infection, seroconversion, asymptomatic, symptomatic and AIDS 
(Figure 3). 
The duration of these phases may vary considerably from patient to patient, but 
despite intense investigation the underlying factors for this remain unclear29'150. 
Fortunately, in the last couple of years, new chemotherapeutic approaches 
(combinational therapy) have extended the asymptomatic phase for many HIV 
-  12 -
infected individuals149. However, currently there is no cure to eradicate HIV in 
the infected individual. Once the virus is transmitted, the virus will replicate in 
the CD4 positive cells in the host, producing vast amounts of circulating virus 
particles (Figure 3 - Plasma RNA). 
Antibodies to p24 
Plasma culture 
Infection 
^ Seroconversion Death 
4^ Asymptomatic Symptomatic AIDS ^ 
=>-1000 
a 
I 500 CD4* PBL 
Ç(asma RNA copies 
Antibodies to HIV env  
/ V HIV specific CIL 
« ''»»g«.,..,..»»«»»»»»»»'"", 
4-8 wks up to more than 12 yrs 2-3 yrs 
Figure Fejl! Ukendt argument for parameter.. Immunological and clinical variables during the course of HTV 
infection. Modified from Profy et al., 1990 164 
Tî*Q1 • 10ß" l'îrt Shortly after infection, specific immune responses against HIV emerge ' ' ' 
(Figure 3 - HIV specific CTL and Antibodies to p24 and HIV env). The specific 
reactivities of CTL and antibodies somewhat controls the viral replication for a 
period of years130, but the CTL and neutralising antibodies are believed to be 
responsible for the constant generation of escape mutants in vivo6. 
In the later course of the asymptomatic phase, the concentration of circulating 
CD4+ T-lymphocytes cells may gradually decline to a critically low level, where 
the immune response no longer can control the replication of the virus or 
ordinary non-pathogenic infections. The progression of this immunodeficiency 
phase eventually leads to uncontrollable immunodeficiency disease and 
ultimately to death of the HIV infected individual. 
- 13 -
Treatment of HIV 
The first anti-retroviral drugs used for treatment of HIV infected individuals 
were inhibitors of the HIV reverse transcriptase (RT) enzyme. These drugs were 
nucleoside analogues that were aimed at inhibiting the reverse transcription step 
in the life cycle of HIV and prevent the subsequent integration of the viral 
genome. Treatment with these nucleoside analogue RT-inhibitors generated 
escape-mutants quickly and was found to have an insignificant influence on the 
clinical course of the disease. However, administration of a nucleoside analogue 
RT-inhibitor for a brief period around the time of delivery can significantly 
reduce the perinatal HIV transmission from mothers to their new-born babies 
from around 25% to 8%36. Pregnant HIV infected individuals are now like other 
HIV infected individuals offered an improved anti-viral drug regimen, which 
reduce the HIV transmission rate at delivery to practically zero121. Treatment of 
HIV and AIDS has undergone considerable change in the last five years. 
Protease inhibitors and non-nucleoside-analogue RT-inhibitors profoundly 
suppress viral replication and even increase the CD4 cell counts when used in 
combination with more ordinary anti-viral drug149. This combination drug 
regimen is called highly active anti-retroviral therapy (HAART). Despite the 
great success of the HAART treatment, adverse effects and resistant viruses to 
the drugs have begun to appear in the patients on HAART115. These problems 
with HAART underscore the importance of developing a long-term therapy 
against HIV and AIDS. 
Infectious cycle of HIV-1 
HIV-1 infects through binding of the virus particles to the CD4+ target cell by 
interactions of the envelope gpl20 with the CD4 molecule and the CCR5 or 
CXCR4 molecules on the membrane of the target cell (primarily T-
lymphocytes)39'120 (Figure 4). Fusion of the two lipid bilayers is mediated by 
conformational changes in the HIV-1 envelope gpl20/gp41 complex58'199. After 
fusion, the HIV core is released into cytoplasm of the target cell and the RNA 
genome is fully reversely transcribed to double stranded DNA. This DNA copy 
-  1 4 -
of the viral genome is transported to the nucleus, where the viral integrase 
mediates integration of the provirus into the host chromosome196'211. In contrast 
to other retroviruses, e.g. MLV, HIV has the ability to infect non-dividing 
cells103;104. The integrated provirus is transcribed into full-length messenger 
RNA (mRNA) transcripts that are subsequently processed and spliced into 
smaller mRNA molecules. These spliced transcripts are translated into the viral 
regulatory proteins, Tat and Rev38. 
Budding Mature HIV 
CD4 & Co-receptor 
Sp-———T—.—--  •• •  Membrane Attachment 
Virus assembly 
Cytoplasm 
UULSL) 
Genomic RNA Entry and particle uncoating 
Regulatory proteins Viral proteins 
Reverse 
transcription 
-Viral RNA 
-Ribosome 
-Viral proteins 
Translation Viral DNA 
Integration 
Transcription 
Nucleus RNA export 
Figure Fejl! Ukendt argument for parameter.. Replication cycle of HIV-1. See text for details. Modified from 
Cann & Karn, 1989 77. 
These two proteins have a significant influence on the levels of transcripts and 
RNA processing and assist in controlling the concerted appearance of viral 
elements needed to produce viral particles37'38. The viral elements assemble on 
the inner side of the cell membrane before a premature viral particle buds off. 
After release of the virus particle from the cell, proteolysis in the particle is 
associated with condensation of the core which is necessary for viral infectivity, 
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but not for particle assembly or release83'155. The HIV particle is now fully 
matured and infectious, and a new infectious cycle can begin (Figure 4). 
Receptors and co-receptors of HIV 
The CD4 molecule was found to function as receptor for HIV infection39, 
82;120and it was the first retroviral receptor to be identified. The infection process 
of HIV is independent of pH, in contrast to e.g. the infection processes by MLV 
and Influenza163'190. Isolates of HIV have been classified according to their 
inversely correlated tropism for either T-lymphocytes (T-tropic, rapid/high) or 
macrophages (M-tropic, slow/low). This classification was based on the 
observation that isolates capable of infecting T-cell lines had reduced capacity to 
replicate in primary macrophages55. In addition, HIV isolates were classified as 
either syncytium inducing (SI) or non-syncytium inducing, according to their 
ability to induce syncytium formation (multinucleated cells derived from fusion 
of cells) in T-cells182. 
Based on several observations it was questioned whether the CD4 molecule was 
neccesary or sufficient for HIV infection e.g. 1) CD4 negative cells, e.g. 
neuronal cells, could be infected when high doses of viruses were used105 2) 
soluble factors from e.g. CD8+ cells could inhibit the HIV infection of CD4+ 
cells198 3) transfer of human CD4 to mouse cells was not sufficient to confer 
HIV infection and replication25'112. Despite intense efforts to discover a missing 
co-receptor it was the findings of three members of the chemokine family, 
namely RANTES, MlP-la and MIP-lß as potent inhibitors of infection of HIV-
1, HIV-2 and SIV35, that led to the identification of the CXCR4 cell membrane 
molecule as a co-receptor for HIV infection53. Based on these two findings the 
CCR5 molecule from the same G-protein coupled seven transmembrane (7TM) 
ß-chemokine receptor family was identified as the co-receptor for most HIV-1 
strains41'44. Additional ß-chemokine receptors (CCR2b, CCR3, CCR8, CCR9, 
CX3CRI, GPR1, STRL33/Bonzo, GPR15/BOB, APJ, ChemR23, BLTR, US28) 
have been identified to support HIV or SIV infection, but their biological 
relevance in vivo remains uncertain119,170'212 (Review15'109). Recently, the co-
receptor binding site has been mapped on the core-structure of gpl2Q96'169. 
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Based on the utilisation of co-receptors CXCR4 or CCR5 a new classification 
system for HIV-1 have been proposed by Berger et al., 199814. Isolates that use 
CCR5, but not CXCR4, are termed R5 viruses and isolates that use CXCR4 and 
not CCR5 are termed X4 viruses. Isolates that use both co-receptors with 
comparable efficiency are called R5X4 viruses. 
Early virus-cell interactions 
The interaction between gpl20 and CD4 promotes a series of conformational 
proteins with respect to the target cell membrane. The binding of CD4 to gpl20 
induces these changes in the conformation of the envelope glycoproteins. 
Furthermore, several has reported that a few neutralising antibodies, sCD4 and 
mutations throughout gpl20 can induce a similar conformational change 
described as an "open" or "activated" conformation of gpl20. These 
conformational changes allow high-affinity interaction with co-receptor, CCR5 
or CXCR4 and a few antibodies directed against this co-receptor binding-
site191,194. The CD4-induced translocation of the V1/V2 loops results in the 
exposure of conserved, discontinuous structures on the HIV-1 gpl20 
glycoprotein recognised by the 17b and 48d monoclonal antibodies. The 17b and 
48d epitopes are proximal to a gpl20 region implicated in chemokine receptor 
binding. A plausible model is that CD4 binding to gpl20 repositions the V1/V2 
stem, allowing the formation of an antiparallel ß-sheet that contributes to the 
chemokine receptor binding. The V3-loop is necessary for infectivity and small 
substitutions can abolish infection completely59. A recent study demonstrated 
that substitution of V3-loop sequences, with that of the sequence from a ß-
chemokine ligand for the HIV co-receptor, preserved infectivity of the mutant 
virus particles210. This indicates that the V3-loop is directly interacting with the 
co-receptor. 
Envelope glycoprotein, gp120 
The HIV-1 env gene encodes the two envelope glycoproteins, gpl20 (surface, 
SU) and the gp41 (transmembrane, TM), that are associated non-covalently in 
heterotrimeric complexes in the cell membrane and subsequently in the viral 
envelope after the viral particle buds off 63;97;199;20°. gp!20 are responsible for the 
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binding and adherence to the target cell, whereas the gp41 are responsible for 
the subsequent penetration and fusion of the membranes of the cell and the 
virus58. Half the molecular weight of gpl20 is derived from the ~500 amino acid 
residues, whereas the other half is derived from more than the 25 fairly 
conserved N-linked oligosaccharides located throughout the protein42'98,100. This 
makes gpl20 the fourth most glycosylated protein known139. gpl20 contains a 
relatively small number (< 10) of O-linked glycans17,68,72,158. The structure of 
some of these O-linked glycans are truncated, but still O-glycosylation of gpl20 
have been shown to significantly contribute to the overall molecular mass17'72. 
The highest diversity in the HIV genome is found in the envelope gene42. 
Variation in gpl20 is not, however, dispersed throughout the entire envelope 
gene, but localised to several regions of lower variation (constant regions) or 
higher variation (variable regions)42'127,188. 
Biosynthesis of gp120 
The viral envelope glycoproteins gp41 and gpl20 are generated by proteolytic 
cleavage of a single precursor protein, gpl60. During synthesis, the protein is N-
glycosylated in the endoplasmic reticulum, where folding and oligomerisation 
into trimers occurs49'97. At this stage, the oligomeric precursor protein gpl60 has 
already acquired the ability to bind CD450. In the Golgi apparatus three 
important events takes place, 1) the gpl60 is endoproteolytically cleaved into 
gp41 and gpl20 2) the gpl20 molecules are modified by addition of O-linked 
glycans and 3) a trimming and addition of carbohydrates on both N- and O-
linked glycans17;68;90;118;157'189;201. After trimming of glycans on the envelope 
products, the envelope complex is transported to the cell membrane for 
subsequent association with viral particles budding off the cell membrane. 
Structure and function of gp120 
The envelope glycoprotein gpl20 was identified as a molecule that induced 
antibodies in AIDS patients3. Sequence homology analysis of many HIV-1 
isolates identified variable regions (VI, V2, V3, V4, V5) regions and constant 
regions (CI, C2, C3, C4, C5, C6)127;188. However, all regions are not equally 
important for viral functions. The V4 and V5-loop seems to be indispensable, 
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whereas the Vl-loop, Vl/V2-loop and the V3-loop is dispensable for 
replication, although associated with a dramatically reduction in 
The extensive glycosylation of gpl20 has for many years made crystalisation of 
gpl20 impossible138. Finally, a structure of gpl20 was deduced from a crystal of 
gpl2096;203. The crystal was made with a deglycosylated core fragment of gpl20 
lacking the VI, V2 V3 loop. The core gpl20 was complexed with a CD4 
fragment and a Fab antibody specific for the CCR5 binding site96'203. The gpl20 
core fragment has preserved the ability to bind CD4 and CCR5 and displays an 
overall conserved antigenic profile19'140'203. The structure of monomeric gpl20 
appears to be composed of an inner-domain and an outer-domain, connected by 
a four-stranded bridging ß-sheet96 203'204 (Figure 5). 
Vira! membrane 
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domain 
Outer 
domain 
(heavily 
glycosylated) 
CD4 
binding site 
Coreceptor 
binding site 
Bridging 
sheet 
Figure Fejl! Ukendt argument for parameter.. Structural model of gp!20. The model is based on the crystal 
structure of the gpl20 core complexed with a CD4 fragment and a Fab fragment speciflc for the CCR5 
binding site 96. Modified from Burton & Parren, 2000 . 
The inner-domain seems to be engaged in association with gp41 and the C- and 
N-terminus of gpl20, whereas the outer domain is mostly exposed on the 
surface of the trimer. The interface between the outer and inner domains of 
gpl20 are devoid of glycosylation and forms the binding sites for CD4 and the 
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co-receptor96'203 (Figure 5). Much of the contact between gpl20 and CD4 seems 
to come from interactions with Ca-atoms of the amino acids of gp!20. Since 
antibodies usually interact with the side chain component of amino acids, this 
allows gpl20 to alter amino acids in the CD4 binding site without sacrificing the 
ability to bind CD4202. Previously, gpl20 was thought to consist of two faces 
only133'134. Elucidation of the structure has revealed a previously unknown face -
the silent face. This face is situated on the outer-domain of gpl20 but protected 
by N-linked glycosylation towards recognition by antibodies96,202. 
A structural comparison of the neutralisation sensitive HXBc2 with the 
neutralisation resistant isolate YU2 have revealed a remarkably similarity of the 
core gpl20 from these isolates95. This study suggested that neutralisation 
resistance is specified by the quaternary interactions of gpl20 involving the 
V1/V2, V3 and V4 loops. 
Biological functions of carbohydrates on gp120 
The huge carbohydrate moiety of gpl20 is an important component of the HIV-
1 envelope glycoprotein in several respects. The glycan structures of gp 120 are 
products of the host chromosome coding, specified by the consecutive actions of 
transferases and glycosidases present in the ER and Golgi. However, the glycan 
structures are affected by the composition of the microcompartment in the ER 
and Golgi and e.g. the production rate of the glycoprotein, which may be 
influenced by the viral infection. Still, all the N-glycosylation sites of gpl20 
have been found to be utilised100;209(I, IV). Abnormal glycosylation patterns and 
aberrant glycan structures have been identified on HIV envelope products not 
normally found in humans17,33'68'72'99'158. 
The carbohydrate moiety is important for gpl20 to attain correct protein 
conformation and CD4 binding capacity19'204. However, once the correct 
conformation is achieved the carbohydrates of gpl20 seem to be dispensable for 
stabilisation of correct conformation. Deglycosylated gpl20 preserves the ability 
to bind CD4 and deglycosylated virus particles can infect cells, although at 
much reduced levels54;96;140'151'203. However, carbohydrates of gpl20 can 
2*21 *85" 86* 137 
significantly influence important functions and the structure gp 120 ' ' ' " . 
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An important role of the carbohydrate moiety seems to be immunoprotection of 
i  cn  i  9Q.  i  o  
gpl20 . Several ' single N-linked glycans, and even also peripheral 
glycosylation, have been reported to influence the immune recognition of gpl20 
9;21';30;69; 177; 178; 148^j 
O-linked glycans of gp120 
The exterior envelope glycoproteins from several retroviruses, including HIV-1, 
have been found to be modified by 0-glycosylation!58. The aberrant short 
chained O-glycosylation such as the Tn antigen which is abnormally expressed 
in number of cancers, have been found on the envelopes from HIV-1 and HIV-
217.55.68.72.158.186^ yj)ese O-linked neoantigens serve as broadly neutralisation 
epitopes and are common on both primary and laboratory adapted strains. The 
N-linked neo-antigens Aj and Le1 have also been identified as neutralising 
epitopes on HIV ' ' . Pre-existing antibody reactivities towards these neo­
antigens has been suggested to be involved in rejection of the initial HIV 
infection145. 
In contrast to N-linked glycosylation, no exact consensus acceptor sequence has 
been identified for O-linked glycosylation, which may be explained by the 
multiple GalNAc transferases identified in the last decade70;71. Initial O-linked 
glycosylation takes place in the cis-Golgi compartment after N-glycosylation, 
folding and oligomerisation of gpl20. Therefore, acceptor sites must be exposed 
on the surface of oligomer gp 120 to be accessible to GalNAc-transferases. Initial 
O-glycosylation is therefore dependent on both local conformation and overall 
tertiary/quaternary structure of the glycoprotein. The role of O-linked glycans on 
gpl20 has so far not been identified. However, O-linked glycans have been 
proposed to alter the recognition by the neutralising antibodies generated in a 
primate host30;148. 
N-linked glycans of gp120 
Individually, every N-linked glycan of gpl20 is dispensable for infectivity98 and 
multiple N-glycan deletions can be accommodated with only an impairment of 
infectivity or even without any apparent loss of viral functions43;69;76;77;108'166. 
However, several functions are affected by single or multiple N-glycans; e.g. 
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binding to CD4 and the co-receptor12'20'75'147,43'45~47'85"87'110'113(I). Recently, the 
conserved N-glycan in the V3-loop of a mutant strain of the NDK X4 isolate 
have been identified as a determining factor for CD4-dependence46'47 (Hazan, 
U., personal communication). N-linked glycan have in many cases been shown 
to modulate the structure of peptides and proteins (Review143). Deletion of N-
glycans of gpl20 can modulate the conformation of gpl20 without changing the 
overall structure 21;85(I, II). Removal of a single N-glycan in the C2-region was 
found to confer CD4 independence. The authors proposed that this was caused 
• 85 by a structural displacement of the whole V 1/V2-region . 
Analysis of the N-linked glycans of gpl20 has identified the presence of both 
high-mannose, hybrid, complex type glycans18'100'125'209. More N-glycan 
subtypes than addition signals have been identified on gpl20, which indicates a 
micro-heterogeneity in the structure of gpl20125. Peripheral glycan structures 
have been shown hide epitopes of gp!2021 and the observed micro-heterogeneity 
may have both structural and antigenic implications. N-linked glycosylation is 
thought to be part of HIV's resistance mechanism in order to protect envelope 
proteins from attack by the host's immune system13'167'187. Insertion of N-
glycosylation sites has in several cases been identified as an escape mechanism 
of gpl20 to shield underlying or distant epitopes against neutralising 
antibodies9'305108'148'166'167'176"178. Both O-linked and N-linked carbohydrate 
structures can be part of an antibody neutralisation epitope68. Antibodies to 
blood group antigens have been found to interfere with viral replication5'68'73. 
However, gpl20 specific antibodies that recognise epitopes containing N-linked 
glycosylation is only rarely found in HIV infected individuals195. 
N-linked glycosylation of gpl20 have also been reported to influence the 
selection of epitopes recognised by T-cells in mice185. The reason for this is 
unknown, but the N-glycans could have altered the processing of the molecule, 
and hereby the subsequent peptide presentation, as seen for other proteins114. A 
recent DNA immunisation study showed that both the glycosylation and the 
conformation of the antigen might dictate the selection of T-helper (Th) cell 
epitopes192. All Th-epitopes induced by DNA immunisation were found to be 
located on the exposed and accessible surface of gpl20 when visualised on the 
i 192 
crystal structure . 
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The glycosylation of gpl20 has been shown to influence sensitivity to 
neutralising antibodies to the V3-loop and the CB4bs, but also to influence the 
binding to CD4 and the co-receptor110:65;69;108;177;178(I). Deletion of the V1/V2-
region of gpl20 confer increased accessibility to neutralising antibodies, sCD4 
and co-receptor28,84'168'205. In spite of the multiple functions of the V1/V2 loop it 
is quite remarkable that viral particles deleted for VI /V2-deieted (ÀV1/V2-
gp 120) still are infectious28'205. This could indicate that the most important 
function of the Vl/V2-region may be to control the interaction with the host cell 
receptors and to modulate the immune recognition of gpl20. 
Immune recognition of HIV 
The HIV infection induces specific immune responses in the host. After the 
initial HIV infection, the virus replicates to high levels before specific immune 
responses appear (see Figure 3). The appearance of HIV-specific CTL's 
coincides with a decline in viral load, whereas antibodies to env appears 
subsequently23,94. The CTL response is therefore believed to control the initial 
HIV infection which is supported by CD8-depletion studies81;130;144;161;175. The 
anti-env antibodies produced within the first year of infection are primarily 
directed against non-neutralising epitopes of gpl2093;128;13°. Autologous 
neutralising antibodies are found approximately one year after infection whereas 
heterologous neutralising antibodies are found one year later128. The reason for 
the slow maturation of the autologous and heterologous neutralising antibodies 
remain unclear. However, most of these matured neutralising antibodies seem to 
recognise conformational epitopes around the CD4 binding site or epitopes 
induced after CD4 binding131. 
The specific immune responses stimulate the generation of escape 
yl.^ .7 .1  AO. 1  O/»« 1  ro  
variants ' ' ' ' ' . Escape mutants are generated by single or multiple amino 
acid substitutions, that often affects the glycosylation sites of 
gpl209'j1'122'126'177,187. The persistence of HIV infection is believed to be caused 
by a constant generation of variants escaping the specific immune responses. 
Evolvement of virus isolates lacking some N-glycosylation signals, have been 
associated with prolonged virus propagation in vitro or progressed disease and 
immunosuppression in vivo106. The variant virus isolates appear to be more 
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aggressive and to primarily utilising the CXCR4 co-receptor for entry9'106,182. 
These viral characteristics are believed to evolve when the immunocomprimised 
host no longer can control the virus imunologically. 
Antibodies to HIV can protect against infection. Several studies have reported 
protection of non-human primates against a virus challenge after passive transfer 
of monoclonal antibodies either alone or in combination with purified antibodies 
from HIV infected primates8'183. These studies encourage the development of a 
potent gpl20 immunogen for an antibody based HIV vaccine. 
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Methods 
Cells and virus 
Cells. The human CD4+ lymphocyte cell lines H9162, C8166172, MT-2 and 
MT-474'154 were obtained through the AIDS Reagent Project, British Medical 
Council (MRC) and grown in complete growth medium with antibiotics (I, II, 
III, IV). The growth medium used for peripheral blood mononuclear cells 
(PBMC) was supplemented with IL-2 (III). 
Virus. The HIV-1 LAI isolate pLAI.2 (formerly pBRU2)11;31'197 was subjected 
to site directed mutagenesis to delete consensus sites for N-linked glycans in the 
Vl-loop (I, IV), V3-loop (II, IV) and potential O-linked glycosylation sites in 
the V3-loop (II). A 2.7 kb BamHI-Sall fragment of pLAI.2 containing most of 
gpl60, was inserted into pUC18 for site directed mutagenesis using mutagenised 
oligonucleotides. All mutants sequences were verified by DNA sequencing. 
Viral stocks were made by transfection of H9 cells with full-length plasmid 
DNA using a modified DEAE-Dextran transfection procedure78. Culture 
supernatant was harvested after 2-4 weeks of culture, 0.45 |nm filtered, aliquoted 
and stored at -70°C until use. All clonal viral stocks were verified by DNA 
sequencing as above (I, II, IV). Viral stocks from HIV infected individuals were 
obtained by cocultivation of OKT4 selected CD4+ cells from patients and 
healthy donorsls"(111). 
Virus titration was done as an end-point titration in MT-4 cells or pooled 
PBMC using quadruplicate or octaplicate cultures and 5-fold viral dilution 
series. Cell Culture Infective Dose 50% (CCID50) was calculated essentially as 
described by Reed & MuenchI65(I, II, III, IV). 
Neutralisation assay. Virus supernatant (25 to 100 CO Dsn) and a dilution 
series of neutralising agent was allowed to interact for 1 hour at RT before 
addition of permissive MT-4 cells for two hours or PBMC for 16 hours. 
Unbound virus was removed by extensive wash and cells were resuspended in 
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appropriate growth medium and quadruplicate cultures were cultured for 4 days 
(MT-4) or 7 days (PBMC) in a 96-well plate (I, II, III). 
Virus phenotype was determined from the ability to form syncytia in the 
isolation culture of CD4+ cells, in the co-culture for virus-propagation or in co-
culture with MT-2 cells180(III). 
CCR5 genotype determinations were done with PCR on genomic extracted 
DNA using primers spanning the potential 32-bp deletion in the CCR5 gene. 
The resulting PCR fragments were small in size for easy visual identification of 
size differences of amplified DNA fragments after agarose gel electrophoresis 
(III). PCR amplification of the wild type CCR5 gene gave a fragment size of 
137 bp. 
ELISA 
HIV Ag ELISA used purified antibodies from HIV infected individuals (HIV 
Ig) as a capture antibody142. HIV antigens were detected using biotinylated- HIV 
Ig followed by HPR conjugated avidin. Colorimetric development from the 
enzymatic conversion of o-phenylenediamine (OPD) was measured at 490 
nm/630 nm (I, II, III, IV). 
gpl20 ELISA used the anti-C5-antibody, D7324 (IV), or the anti-V3-antibody, 
NEA-9205 (II, III) as capture antibody132'135. Serum from HIV infected 
individuals (III), biotinylated HIV Ig (IV) or the anti-V3 -antibody NEA-9205 
(II, III) were sources of detection antibodies. Alkaline phosphatase-conjugated 
secondary antibodies were used with the AM PAK amplification kit (DAKO) 
and measured at 450 nm/630 nm essentially as described123 (II, III). HPR 
conjugated avidin and OPD was used with the biotinylated HIV Ig (IV). 
Radio immunoprecipitation assay RIPA 
3H-G1CNAC labelled gpl20 were incubated with mouse anti-V3 antibody 
NEA9205 (I, II) or the anti-Tn antibody 83D4 (II), and pelleted with a anti-
mouse-Ig coupled to proteinA-Sepharose and subjected to SDS-polyacrylamide 
gelelectrophoresis (SDS-PAGE) for visualisation after exposure to film (I, II). 
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Deglycosylation assay 
Typing of N-glycans (IV) was done with a modified RIPA method; 35 S-
cysteine/methionine labelled gpl20 was caught onto the bottom of a micro well 
using the anti-V3-antibody NEA-9205 as capture antibody, and subjected to 
enzymatic degradation using either Endoglycosidase H or N-glycanase/N-
glycosidase F. Complexes were solubilised by boiling with SDS and DTT for 30 
min., and subjected to SDS-PAGE for visualisation of protein mobility. 
Protection of gpl20 deglycosylation (IV) was determined with a modified 
RIPA deglycosylation procedure; 3H-GlcNAc labelled gpl20 was caught onto 
the bottom of a microwell using either the anti-V3-antibody NEA-9205 or the 
anti-C5 antibody, D7324 as capture antibodies. Wells were preincubated with 
sCD4, NEA9205, D7324, HIV Ig, or serum from HIV infected individuals, 
before subjection to N-glycosidase F degradation. Soluble fractions were 
removed from mierowells and measured for the content of radioactivity. 
Undigested glycans on gpl20 still bound onto the micro well were solubilised by 
boiling with SDS and DTT for 30 min., and measured for the content of 
radioactivity by liquid scintillation. The two measurements of each well were 
used to calculate the degree of inhibition of deglycosylation of gpl20. 
Glycosiciase 
Antibody 
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gpi 20 with 
N-glycans 
Figure Fejl! Ukendt argument for parameter.. A schematic representation of t he deglycosylation assay for 
protection of gpl20. N-glycanase digestion of N-glycans releases them into the reaction buffer. Left: 
Unproteced gpl20 caught onto the microwell with an antibody. Right: Partially antibody protected gpl20 
caught onto the microwell by an antibody (TV) 
- 2 7 -
Summary of results 
N-glycans and modulation of antibody sensitivity 
138 Glycosylation of gpl2() is necessary to attain functional conformation . In 
addition to shielding of peptide stretches around N-linked glycans9'176 the 
glycosylation of gpl20 could also influence the three-dimensional conformation 
of the molecule, and thus influence the presentation and accessibility of epitopes 
in a more indirect and spatially discontinuous manner21,95. 
N-glycosylation mutants of gpl20 lacking glycosylation sites in the VI-loop, 
N116Q, (I) or in the V3-loop, A308 (II) were made. Neither of the mutants 
displayed apparent phenotypic abnormalities and both of the N-glycosylation 
signals in the VI-loop and V3-loop were shown to be utilised, as identified by 
an increased electrophoretic mobility of mutant gpl20 (I, II). In addition, using a 
discriminative deglycosylation assay for either high-mannose or complex type 
N-glycans, both of these N-glycans was found to be of the complex type (IV). 
However, the neutralisation sensitivity of these N-glycan mutants to anti-V3 
antibodies was very different. The A3 08 mutant were more than 100 times more 
sensitive to neutralisation by the anti-V3 antibody NEA9205 than the wild type, 
BRU (II). This topic is contained in the dissertation of Britt Losman107. 
Compared to the wild type, the Vl-glycan deletion mutant NI 16Q was found to 
be three-fold more resistant to neutralisation by the anti-V3-antibody NEA9205. 
Additionally, the N116Q mutant was also three-fold more resistant to 
neutralisation by sCD4, but equal or more sensitive neutralisation by the 
conformation dependent antibody, 2G12 (I). These results indicated that N-
glycans of gp 120 could influence the sensitivity to neutralising antibodies. 
Further, these results indicated that the N-glycan in the VI-loop influenced the 
conformation of gpl20, without changing the overall integrity of the molecule. 
These results are consistent with the proposed structure of gpl2096'203. 
Deletion of potential O-glycans in the V3-loop 
Truncated O-linked oligosaccharides constitute broadly neutralising epitopes on 
gpl2068'72. These epitopes could be situated in the V3-loop33, but their exact 
locations on gpl20 remain unknown. 
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Several mutant HIV-1 infectious clones where some or all potential signals for 
O-linked glycosylation at Serine or Threonines residues in the V3-loop of HIV-1 
gpl20 were deleted by Alanine substitution (Figure 7). None of the mutants 
displayed any apparent phenotypic abnormalities (II). These results indicated 
that the Alanine substitutions in the V3-loop, including the resulting N-glycan 
deletion, did not interfere dramatically with viral replication in cell culture (II). 
Mutant clones were compared with the wild type virus for the sensitivity to 
neutralisation with antibodies specific for the O-linked oligosaccharides Tn or 
sialosyl-Tn. If for instance, a Tn epitope was located on one of these sites, 
deletion of the site would remove a neutralisation epitope and render the virus 
more resistant to the neutralising by Tn antibody. However, none of the mutants 
with deletions of O-glycosylation signals in the Y3 loop displayed any increased 
resistance to anti-Tn or anti-sialosyl-Tn antibodies (II). These results indicated 
that the broadly specific O-linked glycan neutralisation epitopes are located 
outside the V3 loop of gpl20. 
Y AD Jo 
Figure Fejl! Ukendt argument for parameter.. V3 loop of BRU with Serine/Threonine mutation sites by 
shading and epitopes for MAbs NEA-9205 and P4D10 indicated by bold lines. The N-linked 
oligosaccharide at N306 is also indicated. From (II). 
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Accessibility to N-glycans of gp120 
The intermolecular interactions between antibodies, epitopes and N-linked 
glycans are complex and poorly understood145. Elimination of glycosylation 
sites prior to antibody binding may not reveal the whole truth and analysis of 
accessibility of N-linked glycans after binding of ligands to gpl20, may disclose 
important features of N-linked glycan as they appear in the folded and native 
molecule. We had developed a deglycosylation assay for characterisation of N-
glycans types (IV) and developed this assay further to investigate induced 
changes in the orientation dependent susceptibility of N-linked glycans of gp 120 
to enzymatic degradation after binding of gpl20 ligands (IV). 
We achieved orientation-specific exposition of gp 120 in ELISA microplates by 
catching gpl20 from 3H-GlcNAc labelled cultures either by D7324 antibody, 
binding to the C5 domain, or NEA-9205 antibody, binding to the V3 region of 
gpl2048. It was unexpected that the heterologous antibody, NEA-9205 was not 
able to protect gpl20 caught by D7324 and vice versa (IV). This demonstrated 
that antibody binding to accessible gpl20 epitopes per se was not sufficient to 
block adjacent glycans from N-glycanase action. In contrast, sCD4 was able to 
protect gpl20 caught by the anti-C5 antibody from N-glycanase action (IV). 
This suggested that the CD4-binding site is surrounded by multiple vicinal N-
linked glycans. However, pooled HIV IgG was able to better protect gpl20 from 
N-glycanase action when gpl20 was caught by the anti-V3-antibody than with 
the anti-C5 antibody (IV). These results demonstrate that N-linked glycans are 
situated in the vicinity of epitopes recognised by IgG from HIV infected 
individuals but the deglycosylation pattern may suggest that these antibodies 
mainly bind to other faces of gpl20 than the CD4-binding one. 
The specificity of the antibodies produced in vivo during the natural infection 
may influence the progression of the disease. In a small pilot study we wanted to 
explore the orientation dependent susceptibility of gpl20 N-linked glycans to 
enzymatic degradation after binding of sera from HIV infected individuals 
displaying SPI or RPI (III, IV). Three sera from HIV infected individuals 
displaying SPI and two sera from individuals with RPI were found to be able to 
protect gpl20 from N-glycanase action (IV). All five HIV+ sera protected gpl20 
caught with the anti-V3 equally or better than gpl20 caught with anti-C5 
antibody (IV). This indicated that N-linked glycans are situated in the vicinity of 
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epitopes recognised by sera from HIV infected individuals with SPI and RPI. No 
difference between the sera from individuals with slow or rapid progression 
infection could be discerned here. 
Factors influencing disease progression. 
The duration of the asymptomatic phase in untreated HIV infection varies 
considerably among infected individuals and an understanding of the underlying 
reasons for this variation is likely to provide insights into mechanisms to control 
of the disease. We approached this by comparing consecutive pairs of sera and 
HIV-1 isolates from HIV-infected individuals displaying a slow progressing 
infection (SPI) with individuals displaying a rapid progressing infection (RPI). 
We found that neutralising titers of consecutive serum samples against 
autologous virus isolates were generally higher in persons with SPI than in 
persons with RPI (III). However, the presence of autologous neutralising activity 
was not a requirement for SPI. This may indicate a contribution of the cellular 
immune system in controlling the infection136. 
Virus phenotype was determined both by the ability to induce syncytia in the 
isolation culture of CD4+ primary cells and by the ability to establish production 
infection of MT2 cells. We found that 7 of 10 SPI were infected with NSI virus 
compared to the 4 of 10 in the RPI group (III). In addition, we analysed the 
chemokine receptor CCR5 gene for the common 32-bp deletion reported to 
influence viral replication40'52,173. The heterozygous individuals were equally 
distributed in the groups of SPI and RPI (4 of 10), however, a close correlation 
between presence of the deleted allele, virus phenotype (NSI/SI) and SPI/RPI 
status was observed (III). Thus, all heterozygous individuals with SPI were 
infected with NSI virus (4 of 4). In contrast, all heterozygous individuals with 
RPI were infected with SI virus (4 of 4). This difference is statistically 
significant (p=0.029, Fisher exact test). Thus, in this study, heterozygosity for 
the deleted CCR5 allele in conjunction with infection with a NSI isolate was 
predictive for SPI (III). 
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General discussion 
The HIV-1 glycoprotein gpl20 is probably the most glycosylated viral protein. 
Multiple functions are associated with these carbohydrates, but one prominent 
task from the viral point of view, is to block access for potential neutralising 
antibodies to otherwise hidden epitopes at the glycoprotein surface. Available 
data suggest HIV-1 has recruited N-linked glycans for this purpose. On the other 
hand, the host cell may use carbohydrate units at the viral surface for 
counteraction of the viral N-linked glycan-dependent escape from neutralising 
antibodies. This is possible because the strength of the viral strategy to use host 
cell-specific, i.e. "self' carbohydrate sequences for shielding in a sense also is a 
weakness, because of the maintained host control of the glycosylation process. 
Thus, the initiation of the viral transcription program may alter the expression of 
different host glycosyl-transferase genes, resulting in altered or aberrant 
glycosylation of host cell as well as viral proteins. These altered carbohydrates 
may be considered as "non-self' and, therefore, such altered carbohydrate 
determinants of the viral glycoprotein may be attacked by pre-existing, 
circulating, and now, neutralising antibodies to various carbohydrate antigens. 
Here, both these aspects of carbohydrates of viral glycoproteins and antibody 
neutralisation of HIV-1 are discussed. 
The finding that elimination of an N-linked glycan of the V3 region of gpl20 
resulted in a mutant virus that was more than two orders of magnitude more 
susceptible to neutralisation by anti-V3 antibodies (II) supported the notion that 
large N-linked glycans are utilised in a viral strategy to escape potential 
neutralising antibodies30;56;108;179. This was described in the dissertation by Britt 
Losman107. Recent work demonstrates that also glycans situated more distally to 
the V3 region in the primary protein structure may be engaged in shielding of 
the V3 region. Thus, Losman and co-workers found that a mutant HIV-1 lacking 
three N-linked glycans of the VI region, also was more sensitive to anti-V3 
antibodies than wild type virus, whereas glycans of the C2 region seemed to be 
inert in this context108. This probably reflects that the VI region is adjacent to 
V3 in the three-dimensional conformation of the gpl20 oligomer. However, the 
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data of the present study (I) showed, that elimination of only one of the three N-
linked glycans of the VI region resulted in a slightly increased resistance to 
neutralisation by antibodies to V3, which contrast to the findings described 
above for the mutant virus lacking all 3 glycans. Altogether, these data would 
suggest that only one or both of the two N-linked glycans N-terminal or C-
terminal to the 116N-glycan analysed (position 143 c according to the HXB2 
isolate88) are responsible for shielding of the V3 region. On the other hand it has 
been shown that deletion of the entire VI-loop did not increase the sensitivity of 
e.g. V3-loop antibodies28'205'206. However, deletion of a whole loop may have 
other conformational consequences than shielding of the V3-loop. 
The great risk, from the viral point of view, using host cell glycans for shielding 
of B cell epitopes is that the host cell glycosylation machinery may be disturbed 
by the prominent alteration of host cell metabolism during viral replication. In 
particular, the implementation of the viral transcriptional program may affect the 
balance of the often very transiently expressed glycosyl transferases, resulting in 
carbohydrate neoantigens. Such changes have been described for HIV-infected 
cells and include expression of histo-blood group substances in normally 
"silent" T cells, and short O-glycan chains such as Tn and sialosyl-Tn68'72. A 
variety of HIV laboratory strains and patient isolates have been shown to expose 
these antigens from surface-associated gpl20 and these virus strains become 
readily neutralised by suitable anti-carbohydrate antibodies68'72. It is reasonable 
to assume that naturally occurring antibodies to such unintentional viral 
carbohydrate antigens, may help to restrict the spread of HIV-1 from e.g. A-
positive individuals to B- and 0-positive individuals5;68. As the V3-loop 
constitutes a major neutralisation target, we investigated whether genetic 
elimination of potential signals in this region could reduce the viral sensitivity to 
antibodies to O-glycans. However, we found that none of the four potential O-
glycosylation sites in the V3-loop (Threonine301'308'324 and Serine311) harboured 
any detectable O-linked oligosaccharide neutralisation target (II). These data 
suggest that the O-linked glycans, that constitute targets for neutralising 
antibodies may be situated outside the V3-loop or distributed randomly at 
Serines and Threonines located on the surface of gpl20. Indeed, the results 
obtained from the N-glycanase protection assay blocking with antibodies to V3 
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epitopes demonstrated that gpl20 contains relatively large patches free from N-
linked glycans (IV), which could harbour such O-linked glycans. 
The duration of the asymptomatic phase in untreated HIV infection varies 
considerably among infected individuals and an understanding of the underlying 
reasons for this variation is likely to provide insights into the pathogenic 
processes involved in HIV-1 infection and control of the disease. We 
approached this by studying parameters in HIV-infected individuals who 
displayed a rapid progressing infection (RPI) and compared them with 
individuals who displayed a slow progressing infection (SPI). However, this 
approach is limited by being a comparative study where experimentation is not 
possible. We found that titers of consecutive serum samples against autologous 
virus isolates were generally higher in persons with SPI than persons with RPI 
(III). These results are in agreement with others29'150'180. The finding that the 
presence of autologous neutralising activity was not a requirement for SPI is 
intriguing. In these HIV infected individuals, factors other than neutralising 
antibodies must be decisive for the SPI. It is noteworthy that a persistent viral 
replication can occur for an extended period without the significant generation 
of autologous neutralising antibodies. The lack of induction of neutralising 
antibodies may be caused by an immunosuppressed state (for RPI) or 
insufficiently levels of antigen (for SPI)152'181. However, this may indicate a role 
136 for cytotoxic T-cells in the control of disease . 
Glycosylation of gpl20 influences the virus phenotype and the interaction with 
the co-receptor106;182. The two important factors, addressed in the present study 
(III) are likely to have influence on the rate of disease52'173'182. Syncytium 
inducing virus phenotypes appear to be more virulent and emerge late in the 
course of disease182. The mutant allele containing a 32 bp deletion in the CCR5 
gene, found in up to 22% of Northern Caucasian population, have been 
associated with longer AIDS-free survival52'173. But, neither phenotype 
characteristics nor the 32 bp deletion in the CCR5 gene were alone predictive 
for SPI, as they were represented in both groups (III). The överrepresentation of 
SI in the RPI group is consistent with the progressed stage of disease seen these 
individuals182. However, NSI phenotype in conjunction with the presence of the 
32-bp deletion in the CCR5 gene was predictive for SPI (III). These findings are 
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consistent with the notion that NSI and SI viruses utilises the CCR5 and the 
CXCR4 co-receptors, respectively14, and in accordance with the observation by 
Michael et al.124. The observed correlation between SPI and NSI phenotype in 
conjunction with heterozygosity for the 32 bp deletion in the CCR5 gene did not 
include all the individuals displaying SPI. It is reasonable to believe that the 
underlying reasons for slowly progressing disease of course may be multi­
factorial, and other immunological, virological or host factors are likely to be 
responsible for the slow progression of disease 6;111;150;156;171. 
The HIV-1 gpl20 is extraordinary highly glycosylated67 and contains more than 
20 sites for N-linked glycosylation, most of which are occupied by any of the 
two classes of N-linked glycans, complex type on one hand and high mannose or 
hybrid glycans on the other18'100'209. The most important role of these N-glycans 
seems to be to participate in HIV-1 immune escape mechanisms, by virtue of the 
capacity of the large N-linked glycans to block access to adjacent peptide 
epitopes and functional regions9'65'69'85'146'177. The glycans of all the 
glycosylation sites gpl20 have been classified as either high mannose or 
complex type100. However, the viral isolate LAI contains one glycosylation site 
not present in strain BH10 analysed by Leonard et al.100. Using our newly 
developed deglycosylation assay we found that the last uncharacterised N-linked 
glycan in the VI-loop of the HIV-1 prototype strain LAI in fact is of the 
complex type which is similar as for the other glycosylation sites of this 
region100 (IV). The exposed variable loops of gpl20 contains significant 
sequence variation in response to immune reactivities7'28'56'95'205. In addition, N-
glycans of the complex type are primarily found in exposed regions of 
gpl2Q100'209. Our characterisation of the N-linked glycan in the Vl-loop was 
based on deletion of the N-glycan in question, which could influence the 
processing of other N-linked glycans of the molecule. Still, we believe that 
exposition of the Vl-loop to glycanases and glycosidases in the ER and Golgi 
apparatus is likely to confer the complex nature of this N-glycan. 
The interplay between antibodies, epitopes, and N-linked glycans in immune 
escape mechanisms is complex145, and the approach of elimination of 
glycosylation sites prior to antibody binding may not reveal the whole truth. 
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Thus, analysing the accessibility of N-linked glycans after binding of critical 
monoclonal antibodies or other important ligands to gpl20 may disclose 
important features of N-linked glycan interference with the presentation of 
gpl20, e.g. to estimate the proportion of physically accessible glycans in the 
vicinity of important epitopes such as they appear in the folded, native molecule. 
We further developed the in-well deglycosylation assay to. investigate induced 
changes in the orientation dependent susceptibility of N-linked glycans of gpl20 
to enzymatic degradation after binding of monoclonal antibodies (IV). It is 
interesting that the anti-V3 MAb could not protect gpl20 from N-glycanase 
action and reflects probably that there are too few glycans in the vicinity of the 
V3 region on monomer gpl20 to induce a detectable protection. This is 
noteworthy considering that gpl20 contains more than 20 large N-linked 
glycans100 and that the IgG molecule is even more spatious than gp!20. Thus, in 
spite of the large proportion of glycans on gpl20, there must be relatively large 
96*202*203 patches on monomer gpl20 not occupied by carbohydrates ' ' . 
In contrast, the high degree of protection of gpl20 caught by an anti-C5 
antibody from N-glycanase action by incubation with sCD4, suggested that the 
CD4-binding site is surrounded by multiple vicinal N-linked glycans. The 
presence of bulky glycans surrounding the CD4 binding domain could protect 
the CD4 binding site from antibody recognition. This is in agreement with other 
reports that demonstrate that the actual CD4 binding site differs from epitopes 
recognised by CD4 blocking antibodies and consistent with the deduced crystal 
structure of gpl2096;133:134;203. 
Protection of gpl20 from N-glycanase action was also observed when IgG 
antibodies from pooled HIV infected individuals were analysed (IV). However, 
the most pronounced protection was observed for gpl20 caught with the anti-V3 
antibody and not with the anti-C5 antibody as seen for sCD4-induced protection. 
The results demonstrate that N-linked glycans are situated in the vicinity of 
epitopes recognised by IgG from HIV infected individuals. The deglycosylation 
pattern suggests that these antibodies mainly bind to other faces of gpl20 than 
the CD4-binding one, which may reflect a viral strategy to escape neutralisation. 
The specificity of the antibodies produced in vivo during the natural infection 
has been intensively investigated. Thus, gpl20 antibodies produced in vivo, are 
- 3 6 -
at least partly, directed to non-neutralising epitopes not present on the oligomer 
structure, whereas the majority of the broadly neutralising antibodies are 
directed against the CD4 binding site24;93;130'131. However, the fraction of 
antibodies recognising non-neutralising epitopes present on monomeric gpl20, 
but not oligomeric gpl20, still remains unknown, but may constitute as much as 
half of the circulating anti-gpl20 antibodies24. Shedded monomer gpl20 from 
infected cells or virions has been proposed to act as a decoy antigen and to 
stimulate the production of antibodies against non-neutralising epitopes 
harmless for the virus24;152. The results with HIV Ig presented here (IV) may 
partly reflect this phenomenon. 
We explored possible induced changes in the orientation dependent 
susceptibility of gpl20 N-linked glycans to enzymatic degradation after binding 
of sera from HIV infected individuals displaying SPI or RPI in a small pilot 
study (IV). Sera from HIV infected individuals displaying SPI (three sera) or 
RPI (two sera) were tested and found to protect gpl20 from N-glycanase action 
to various extents. All five HIV+ sera protected gpl20 caught with the anti-V3 
equally or better than gpl20 caught with anti-C5 antibody, confirming that N-
linked glycans also are situated in the vicinity of epitopes recognised by sera 
from HIV infected individuals with SPI and RPI. However, the orientation of 
gpl20 appeared to have little influence on the degree of protection seen for all 
the IIIV+ sera. No difference between the sera from individuals with slow or 
rapid progression infection could be discerned here. 
It has become increasingly clear that development of an HIV vaccine should aim 
at inducing high-affinity neutralising antibodies capable of neutralising several 
isolates. The established protection of HIV infection after passive transfer of 
anti-gp 120 antibodies to a non-human primate was a hallmark for the 
development of an antibody based HIV vaccine116;183. The induction of these 
potent anti-gp 120 neutralising antibodies seems, however, to be a rare event in 
humans195, and current vaccine approaches aim at inducing humoral as well as 
cellular immune responses161. An exiting approach is generation of an 
immunogen based on stabilised oligomeric structures of gpi2095;97;174;202;207;208, 
which is likely to induce both humoral and cellular immunity. Immunisation 
with gpl20 carrying specific N-glycan deletions, is likely to unshield epitopes of 
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gp 120 and to facilitate presentation of a more antigenic structure for the 
stimulation of high-affinity gpl20 antibodies and potent HIV specific T-
cells22;136;167;176;185. Protection from host defences may prove to be the true role 
of the extensive glycosylation of HIV-1 gpl20. One conclusion of the present 
work is therefore that an optimal vaccine, with the ability to induce neutralising 
antibodies and not only cell mediated immunity, must present stable oligomeric 
gp41/gpl20 units, where strategical epitope-masking N-linked glycans are 
eliminated, but where the remaining N-glycans resemble the authentic gpl20 
glycosylation. 
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